HOUSTON--(BUSINESS WIRE)--Edgeline Holdings, Inc. (OTCBB:ELHI), which recently announced a name change to Oncolin Therapeutics, Inc., has agreed to the terms of a license for a key patent that involves the synthesis of 2-deoxy sugars and their derivatives. This enabling patent provides processes to synthesize compounds that would otherwise be difficult and expensive to prepare with high purity and steroselectivity. These compounds are the lead drugs in the company’s antimetabolite development program focused on the treatment of cancers, especially brain tumors.
